It was with grave concern that I read a recent case report by Drs Gavras and Gavras in the January 27, 2003, issue of the ARCHIVES.1 Their report described no incidents of angioedema following the use of angiotensin receptor antagonists (ARBs) in 10 patients who had previously incurred angioedema secondary to the use of angiotensin-converting enzyme (ACE) inhibitors.1 Their case report omitted numerous findings from the literature, and as a result the authors' conclusion is dangerously misleading.